AbbVie (NYSE:ABBV) has been actively advancing its oncology portfolio with recent presentations at the AACR Annual Meeting, ...

AbbVie (NYSE:ABBV) recently showcased significant advances in oncology, particularly with the introduction of new pipeline ...

Data for ABBV-969, a novel STEAP1/PSMA dual-targeted antibody-drug conjugate (ADC) in Phase 1 for advanced prostate cancer, will be presented in an oral presentation. Data to be presented on ABBV ...

Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

AbbVie (ABBV) closed the most recent trading day at $213.85, moving -0.29% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.07%. At the same ...

Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of ...

particularly with the introduction of new pipeline products like ABBV-969 and ABBV-514 at the AACR Annual Meeting 2025, reflecting a commitment to innovative cancer treatments. Despite a downturn ...